Splice it up: Atypical transcripts to boost leukemia immunotherapy

Nicoletta Cieri¹, Catherine J Wu²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: cwu@partners.org.

PMID: 33852826
DOI: 10.1016/j.immuni.2021.03.016

Free article

Comment

Splice it up: Atypical transcripts to boost leukemia immunotherapy

Nicoletta Cieri et al. Immunity. 2021.

Free article

. 2021 Apr 13;54(4):608-610.

doi: 10.1016/j.immuni.2021.03.016.

Authors

Nicoletta Cieri¹, Catherine J Wu²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: cwu@partners.org.

PMID: 33852826
DOI: 10.1016/j.immuni.2021.03.016

Abstract

Neoantigens are prime targets for cancer immunotherapy, but their identification in low mutational burden malignancies remains challenging. In this issue of Immunity, Ehx et al. show that atypical transcripts, and particularly retained introns, expand the spectrum of leukemia immunotherapy targets.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests C.J.W. is an equity holder of BioNTech and receives research funding from Pharmacyclics. C.J.W. has filed patent applications on personalized cancer vaccines entitled as follows: “Compositions and methods for personalized neoplasia vaccines,” “Methods for identifying tumor specific neo-antigens,” and “Combination therapy for neoantigen vaccine.” N.C. has no competing interests.

Comment on

Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes.
Ehx G, Larouche JD, Durette C, Laverdure JP, Hesnard L, Vincent K, Hardy MP, Thériault C, Rulleau C, Lanoix J, Bonneil E, Feghaly A, Apavaloaei A, Noronha N, Laumont CM, Delisle JS, Vago L, Hébert J, Sauvageau G, Lemieux S, Thibault P, Perreault C. Ehx G, et al. Immunity. 2021 Apr 13;54(4):737-752.e10. doi: 10.1016/j.immuni.2021.03.001. Epub 2021 Mar 18. Immunity. 2021. PMID: 33740418

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Splice it up: Atypical transcripts to boost leukemia immunotherapy

Affiliations

Splice it up: Atypical transcripts to boost leukemia immunotherapy

Authors

Affiliations

Abstract

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical